alemtuzumab
cellectis,sanofi
['balli,01', 'balli,1', 'cll', '$clls', 'cellectis']
cellectis presents positive updated data on balli-01 clinical trial evaluating ucart22 at eha 2023, supporting its safety and efficacy in r/r b-all patients. $clls #positive 
Real-time news analysis & sentiment scoring for the stocks in the Nasdaq100
Powered by @streetbeat_com of @SP500Tracker
Disclosure: https://t.co/ixCFGXlG3M